Volume 6.37 | Sep 22

Pancreatic Cell News 6.37 September 22, 2015
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PACN on Twitter
 
TOP STORY
Combination Drug Therapy Shrinks Pancreatic Tumors in Mice
A combination of two drugs, one already approved by the Food and Drug Administration, appears to be effective at shrinking pancreatic cancers in laboratory mice. The drugs, which affect the structure and function of the cancer cell’s DNA rather than the activity of its proteins, also slowed the growth of human lung cancer cells in mice. [Press release from Stanford University School of Medicine discussing online prepublication in Nature Medicine] Press Release | Abstract
Request a Sample: ReproTeSR™
 
PUBLICATIONS (Ranked by impact factor of the journal)
DIABETES & PANCREATITIS

Inhibition of Hyaluronan Synthesis Restores Immune Tolerance during Autoimmune Insulitis
Researchers demonstrated that hyaluronan (HA) is critical for the pathogenesis of autoimmune diabetes. Using the DO11.10xRIPmOVA mouse model of type 1 diabetes, they determined that HA deposits are temporally and anatomically associated with the development of insulitis. [J Clin Invest] Full Article | Press Release

Isocitrate-to-SENP1 Signaling Amplifies Insulin Secretion and Rescues Dysfunctional β Cells
Investigators showed that the cytosolic isocitrate dehydrogenase-dependent generation of NADPH and subsequent glutathione reduction contribute to the amplification of insulin exocytosis via sentrin/SUMO-specific protease-1 (SENP1). [J Clin Invest] Full Article | Press Release

The mRNA-Binding Protein HuR Promotes Hypoxia-Induced Chemoresistance through Posttranscriptional Regulation of the Proto-Oncogene PIM1 in Pancreatic Cancer Cells
Investigators demonstrated that cis-acting AU-rich elements present within a 38-base pair region of the PIM1 (proviral integration site for moloney murine leukemia virus 1) mRNA 3′-untranslated region mediate a regulatory interaction with the mRNA stability factor HuR (Hu antigen R) in the context of tumor hypoxia. [Oncogene] Abstract

Autocrine Action of IGF2 Regulates Adult β Cell Mass and Function
Scientists studied mice with β cell-specific inactivation of Igf2 (βIGF2KO mice) and assessed β cell mass and function in ageing, pregnancy, and acute induction of insulin resistance. [Diabetes] Abstract

Induction of the ChREBPβ Isoform Is Essential for Glucose-Stimulated Beta Cell Proliferation
Researchers found that carbohydrate responsive element binding protein (ChREBP) is highly expressed in response to glucose, particularly with prolonged culture in hyperglycemic conditions. In addition, siRNAs that knocked down ChREBPβ transcripts without affecting ChREBPα expression or activity, decreased glucose-stimulated expression of ChoRE-containing genes and glucose-stimulated proliferation in INS-1 cells, and in isolated rat islets. [Diabetes] Abstract

The β-Cell GHSR and Downstream cAMP/TRPM2 Signaling Account for Insulinostatic and Glycemic Effects of Ghrelin
They authors report that ghrelin attenuates glucose-induced insulin release via direct interaction with ordinary growth hormone secretagogue-receptor (GHSR) that is uniquely coupled to novel cAMP/TRPM2 signaling in β-cells, and that this β-cell GHSR with unique insulinostatic signaling largely accounts for the systemic effects of ghrelin on circulating glucose and insulin levels. [Sci Rep] Full Article

Transient Receptor Potential Channel Vanilloid Type 6 (TRPV6)
Researchers characterized the role of TRPV6 in controlling calcium signaling, cell proliferation as well as insulin expression, and secretion in experimental INS-1E beta cell model. [Biochim Biophys Acta] Abstract

PANCREATIC CANCER

CD146 Attenuation in Cancer-Associated Fibroblasts Promotes Pancreatic Cancer Progression
Investigators clarified the function and significance of CD146 expression in pancreatic cancer. Blocking CD146 expression in cancer associated fibroblasts significantly enhanced tumor cell migration and invasion in a co-culture system. [Mol Carcinog] Abstract

Lysophosphatidic Acid Induces Both EGFR-Dependent and EGFR-Independent Effects on DNA Synthesis and Migration in Pancreatic and Colorectal Carcinoma Cells
Researchers investigated the effects of lysophosphatidic acid (LPA) on DNA synthesis and migration in a panel of pancreatic and colon cancer cells, with particular focus on the involvement of the epidermal growth factor receptor (EGFR) in LPA-induced signaling. [Tumor Biol] Abstract

Manganese Superoxide Dismutase Expression Is Negatively Associated with MicroRNA-301a in Human Pancreatic Ductal Adenocarcinoma
Researchers investigated whether the microRNA (miR)-301a expression level is associated with manganese superoxide dismutase (MnSOD) expression in human pancreatic ductal adenocarcinoma (PDAC). They established a xenograft PDAC mouse model using transfected PanC-1 cells to investigate tumor growth and the interaction between MnSOD and miR-301a. [Cancer Gene Ther] Abstract

Tetraspanin 1 Is Involved in Survival, Proliferation and Carcinogenesis of Pancreatic Cancer
Transfection with siRNA-targeting tetraspanin 1 (Tspan1) significantly decreased proliferation, increased the apoptosis and reduced migration and invasion of AsPC-1 and PANC-1 cells. [Oncol Rep] Abstract

Differentiation Doesn't Have to be Difficult - Get Easy, Standardized hPSC Differentiation
 
REVIEWS
The Emerging Roles of F-Box Proteins in Pancreatic Tumorigenesis
The authors focus on β-TrCP (β-transducin repeat-containing protein) and two other prototypical mammalian F-box proteins, Fbxw7 and Fbxw8, in pancreatic tumorigenesis and progression. They highlight the functions and regulation of these F-box proteins, their respective substrates and cross-talks with other key signaling pathways. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
 
INDUSTRY NEWS
Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study
Sanofi announced that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin. [Sanofi] Press Release

Caladrius Biosciences and Sanford Research Establish Strategic Collaboration with Goal of Developing Major Advance in Treatment of Type 1 Diabetes
Caladrius Biosciences, Inc. announced that it has entered into a collaboration agreement with Sanford Research to develop the company’s T regulatory cell therapy product candidate, CLBS03, for the treatment of adolescents with recent-onset type 1 diabetes. [Caladrius Biosciences, Inc.] Press Release

€3.3 Million Funding for DCU Transatlantic Pancreatic Cancer Research
Researchers at the University at Buffalo, Dublin City University (DCU) and Queen’s University Belfast have secured over €3.3 million to develop an enhanced treatment program for pancreatic cancer. [Dublin College University] Press Release

Groundbreaking Set for Additional Kimmel Cancer Center Building
The Johns Hopkins Kimmel Cancer Center broke ground September 10 on a new $100 million, 184,000-square-foot cancer care building. Slated to open in late 2017, the building is named for Albert P. “Skip” Viragh Jr., a Maryland mutual fund investment leader, philanthropist and pancreatic cancer patient treated at Johns Hopkins who died of the disease in 2003 at age 62. [Johns Hopkins Medicine] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Global Cancer Summit 2015
November 18-20, 2015
Bangalore, India

NEW Innovation and Biomarkers in Cancer Drug Development (IBCD) 2015
December 3-4, 2015
Brussels, Belgium

Visit our events page to see a complete list of events in the pancreatic cell community.
 
JOB OPPORTUNITIES
NEW Marketing Manager – Oncology (Celgene Corporation)

NEW Research Technician – Diabetes & Metabolism (University of Bristol)

Postdoctoral Fellowship – Action in Obesity and Diabetes Pathogenesis (National Institutes of Health Diabetes)

Postdoctoral Fellow – Diabetes and Metabolism (Johns Hopkins University)

Postdoctoral Position – Pancreatic Cancer (University of California, San Diego)

Postdoctoral Position – Diabetes (Harvard Medical School)

Postdoctoral Position – Diabetes Research (Inserm)

Postdoctoral Position – Diabetes Research (Albert Einstein College of Medicine of Yeshiva University)

Postdoctoral Research Fellow – Translational Research Program (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Scientist – Pancreatic Cancer (Columbia University)

Postdoctoral Research Fellow – Development and Pathogenesis of Pancreatic Cancer (University College London)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us